Is NCT06315257 recruiting in Birmingham, AL?

Yes, NCT06315257 is currently recruiting participants at its Birmingham, AL location. This cervical cancer clinical trial is actively enrolling qualified participants.

How do I join the cervical cancer clinical trial in Birmingham?

To join this clinical trial in Birmingham, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Birmingham clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Cervical Cancer Clinical Trial in Birmingham, AL

Who Can Participate

Inclusion Criteria

Female subjects age 18 years or older with diagnosis of advanced (stage IB1-IVA) HPV+ cervical cancer and have completed primary treatment (consisting of any of the following as per NCCN guideline standard of care: surgical resection, radiation, and/or platinum-based chemotherapy) within the past 12 months. Patients who are recommended to receive anto-PD-1 or anti-PD-L1 therapy after chemoradiation are eligible to enroll and can continue to receive such therapy while receiving study drug.

No history of or current evidence of residual disease or disease recurrence based on imaging and clinical assessments within 8 weeks of enrollment

HIV uninfected

Hepatitis B surface antigen negative

Anti-hepatitis C (HCV) antibody negative or negative HCV polymerase chain reaction (PCR)

Patients who are able and willing to comply with all study procedures and voluntarily sign an informed consent form

Adequate organ function as defined by the following parameters:

white blood cell count ≥ 3,000 cells/cu mm

lymphocyte number ≥ 500 cells/cu mm

absolute neutrophil count ≥ 1,000 cells/cu mm

platelets ≥ 90,000/cu mm

hemoglobin ≥ 9 g/dL

total bilirubin \<1.5 X upper limit of normal (ULN), \<3 x ULN if Gilbert's disease

Aspartate Transferase(AST) and Alanine Transaminase (ALT) \<3 X ULN

creatinine \< 1.5 X ULN or estimated creatinine clearance ≥ 60 ml/min per Modified Cockcroft-Gault Formula

Eastern Cooperative Oncology Group performance status of 0 or 1

All clinically significant toxicities related to prior therapy should be less than or equal to Grade 1 at time of enrollment

Ability and willingness for one month post vaccination to follow vaccine inoculation site care and avoid close social contact with children under 1 year old or close social or domestic contact with a pregnant woman or individuals at high risk of serious adverse effects of vaccinia virus, for instance, those with past or present eczema, or immunodeficiency states including HIV infection

Exclusion Criteria

Women of child-bearing potential (i.e., those who have had fertility-sparing procedures for the management of cervical cancer) will be excluded unless agreed to remain sexually abstinent or have a partner who is sterile (i.e. vasectomy), or use methods of contraception (e.g., oral contraception, barrier methods, spermicide, intrauterine device (IUD)), throughout the first 6 months of the study.

Because there is a risk for adverse events in nursing infants, breastfeeding must be discontinued if the mother is treated on study.

Diagnosed with a recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; patients diagnosed with acquired, hereditary, or congenital immunodeficiencies

Diagnosis with a medical condition that requires systemic treatment with immunosuppressive drugs such as cyclosporine, adrenocorticotropic hormone (ACTH), alkylating agents, antimetabolites, radiation, Tumor Necrosis Factor (TNF) inhibitors, or systemic corticosteroids, either chronically or within 30 days of first PVX7 vaccination.

Administration of any blood product within 30 days of signing informed consent.

Need for ongoing therapeutic anticoagulation during the study period due to concern for increased risk of bleeding.

Previous severe allergic reaction or hypersensitivity to a vaccine or any of its components

Participation in a study with an investigational compound or device within 30 days of signing informed consent

Known active central nervous system disease

Surgery within 30 days of first PVX7 vaccination, excluding minor procedures

Diagnosis with an uncontrolled intercurrent illness including, but not limited to, ongoing, or active infection, or psychiatric illness/social situations that would limit compliance with study requirements

Diagnosis with an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis)

History of myocarditis or pericarditis.

Known underlying heart disease (e.g., cardiomyopathy, congestive heart failure, symptomatic arrhythmia not controlled by medication, unstable angina, history of acute myocardial infarction or cerebrovascular accident within the past 6 months).

Patients and the patients close social, sexual, or domestic contacts may not have non-healed wounds or active exfoliative skin conditions such as: Eczema, Burns, Impetigo, Varicella-zoster virus infection, Herpes simplex virus infection, Severe acne, Severe diaper dermatitis with extensive areas of denuded skin, Psoriasis, Lichen planus, Darier disease (keratosis follicularis).

History or presence of atopic dermatitis

Inability or unwillingness to for one month post vaccination follow vaccine inoculation site care and avoid social contact with children under 1 year old or close social or domestic contact with a pregnant woman or individuals at high risk of serious adverse effects of vaccinia virus, for instance, those with past or present eczema, or immunodeficiency states including HIV infection

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Birmingham?

Yes, this clinical trial (NCT06315257) has an active research site in Birmingham, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cervical Cancer Treatment Options in Birmingham, AL

If you're searching for cervical cancer treatment options in Birmingham, AL, this clinical trial (NCT06315257) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Birmingham research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced cervical cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cervical cancer clinical trials near you to find additional studies recruiting in your area.

Cervical Cancer Clinical Trial in Birmingham, AL

Expert Care in Birmingham

IRB Approved

No-Cost Care

Apply for This Birmingham Location

Why Participate?

Simple Process

About This Cervical Cancer Study in Birmingham